Zeo ScientifiX (ZEOX) 10-Q2023 Q1 Quarterly report

Filed: 17 Mar 23, 4:15pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. senior Bad

New words: breakeven, Center, Collaborative, Confidential, confidentiality, Davie, downturn, eligible, entertainment, escrow, forgiven, global, immaterial, LA, memorializing, Nova, occupied, piggyback, pooled, President, Qualitative, Quantitative, redeposited, relocated, rescind, resignation, resigned, Science, shorter, Southeastern, travel, treasury, University, vesicle, Vice

Removed: accredited, achievement, advanced, advertising, afforded, al, Allen, amortize, arrangement, awarded, bank, brokerage, calendar, Carbonara, CMO, collected, consecutive, contract, controlled, converted, copier, Dade, Darbie, dealing, Deceptive, decision, distinguish, education, eighteen, employed, enrichment, enrolled, excluding, exempt, exemption, existed, Expanded, expansion, extend, extended, extent, faith, fix, fraudulent, healthcare, iii, incentive, Incorporation, increasing, independent, initiated, International, internet, iv, LAE, large, law, Livin, loan, managed, maturity, MCPP, Meglin, Michael, milestone, million, misrepresentation, negligent, offer, owed, owing, par, periodic, Phase, placental, point, preferred, prescribed, pricing, proforma, promulgated, reached, realize, reimburse, reliance, renewable, repaid, representing, Rover, satisfactorily, served, serving, styled, subscription, thereunder, thirteen, Trade, twelve, twenty, unexchanged, Unfair, unjust, unsecured, violation, VP

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

ZEOX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Organicell Regenerative Medicine, Inc. on Form 10-Q for the quarter ended January 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned Ian T. Bothwell, Interim Chief Executive Officer and Chief Financial Officer (principal executive, financial and accounting officer) of Organicell Regenerative Medicine, Inc., a Nevada corporation (the “Company”), hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Organicell Regenerative Medicine, Inc.

Date: March 17, 2023	/s/ Ian T. Bothwell
	Ian T. Bothwell
	Interim Chief Executive Officer and Chief Financial Officer
	(Principal Executive, Financial and Accounting Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.